Sentences with phrase «cancer research advance»
Tags: Dr Vincent Chung, Dr Yuman Fong, Liver cancer, cancer research advances, gene therapy, immunotherapy, viral gene therapy
https://www.cityofhope.org/ Not exact matches
His research has spanned hematopoiesis, gene therapy, stem cell biology, genomics and cancer, consistently focusing on bringing the very latest research advances to patients with heretofore incurable diseases.
PERTH - based Medi - tech Research Limited may be on the brink of a major advance in cancer therapy with its hyaluronic acid technology for the delivery of anti-cancer drugs.
The corporation was spun out of the Ontario Institute for Cancer Research (OICR) to develop and advance late pre-clinical, Phase I or early Phase II potential products.
Prior to joining the OCC, Rossi most recently served as President and CEO of Prostate Cancer Canada where he helped to advance the research, advocacy, education and awareness of the most common cancer iCancer Canada where he helped to advance the research, advocacy, education and awareness of the most common cancer icancer in men.
We witness the marvels of technology which have been made possible through the advances of science, and we wait hopefully for the results of continuing research, for example in the cancer field.
Advancing a reason - based scientific world view will advance the causes of cancer research and world hunger.
How about donating to help others — advancing cancer research, or feeding the homeless, etc.?
Grateful for support we've received in memory of @Jeopardy champion Cindy Stowell, who donated winnings to help advance cancer research pic.twitter.com/SJZv0oVw 5t
10 % of each sale of this beautiful baby carrier will be benefit the Breast Cancer Research Foundation, whose mission is to prevent and cure breast cancer by advancing the world's most promising resCancer Research Foundation, whose mission is to prevent and cure breast cancer by advancing the world's most promising rResearch Foundation, whose mission is to prevent and cure breast cancer by advancing the world's most promising rescancer by advancing the world's most promising researchresearch.
Regenerating organs for patient transplants, research and policy questions for «smart» vehicles, advances in the fight against cancer, and voter participation in elections will be discussed in Austin, Texas at the 2018 American Association for the Advancement of Science (AAAS) Annual Meeting, the...
She fostered cross-disciplinary, cross-institutional and cross-national initiatives, among them the Koch Institute for Integrative Cancer Research, the MIT Energy Initiative and the Massachusetts Green High - Performance Computing Center, and she co-chaired the White House's Advanced Manufacturing Partnership.
A group of the nation's leading cancer research scientists and their Cuban counterparts are exploring how to advance cancer therapy, diagnosis, and prevention, including the use of immunotherapy to harness the body's immune systems to attack and eliminate cancer cells.
«Several major advances in recent years have been good news for multiple myeloma patients, but those new drugs only target terminally differentiated cancer cells and thus can only reduce the bulk of the tumor,» said Jamieson, who is also deputy director of the Sanford Stem Cell Clinical Center, director of the CIRM Alpha Stem Cell Clinic at UC San Diego and director of stem cell research at Moores Cancer Center at UC San Diego Hcancer cells and thus can only reduce the bulk of the tumor,» said Jamieson, who is also deputy director of the Sanford Stem Cell Clinical Center, director of the CIRM Alpha Stem Cell Clinic at UC San Diego and director of stem cell research at Moores Cancer Center at UC San Diego HCancer Center at UC San Diego Health.
The research, which appears today as an advance online publication in the journal Nature, should aid development of more personalized cancer immunotherapy and advance diagnosis and treatment of infectious diseases.
However, new research from the University of Copenhagen reveal that the infections may even benefit the cancer cells, because the toxins in certain staphylococcus bacteria make healthy cells produce substances that in fact advance their growth.
If hypofractionated radiation with curative intent can reduce the treatment time for lung cancer patients by half with no greater toxicity, and with equivalent — if not better — tumor control and survival outcomes, this research could result in a change in the paradigm of how a large subset of locally advanced NSCLC patients are treated.»
«Steep funding cuts for the federal health agencies are counterproductive at a time when innovative research is moving us closer to identifying solutions for rare diseases, new prevention strategies to protect Americans from deadly and costly conditions, advances in gene therapy, new technologies for understanding the brain, and treatments that harness the ability of our immune system to fight cancer.»
One bright spot is that the proposal includes funding mandated by the 21st Century Cures Act for the Obama administration's cancer moonshot, Brain Research through Advancing Innovative Neurotechnologies neuroscience initiative, and Precision Medicine Initiative's planned 1 - million - volunteer health study.
A clinical trial conducted by researchers at the Virginia G. Piper Cancer Center Clinical Trials, a partnership between Scottsdale Healthcare and the Translational Genomics Research Institute (TGen), showed that a new drug called MM - 398, given in combination with 5 - flourouracil (5FU) and leucovorin, produced a significant overall survival rate in patients with advanced, previously - treated pancreatic cCancer Center Clinical Trials, a partnership between Scottsdale Healthcare and the Translational Genomics Research Institute (TGen), showed that a new drug called MM - 398, given in combination with 5 - flourouracil (5FU) and leucovorin, produced a significant overall survival rate in patients with advanced, previously - treated pancreatic cancercancer.
The research was published in the Jan. 18 issue of Molecular Carcinogenesis, which focused on recent advances in lung cancer.
«The abstracts we presented at WCLC are prime examples of how our growing body of research and studies at CTCA at Western are advancing medicine and hold the potential to provide patients with better cancer treatments,» Dr. Weiss said.
New products and developments, such as new drugs for cancer, fresh therapies for rare diseases, progress in medications for HIV / AIDS, and advances in stem cell research had the greatest positive impact.
Other UT Southwestern faculty members who contributed to this research are: Dr. Boning Gao, Assistant Professor with the Hamon Center for Therapeutic Oncology Research and Pharmacology; Dr. Kimmo Hatanpaa, Associate Professor of Pathology; Dr. Kemp Kernstine, Professor of Cardiovascular and Thoracic Surgery and holder of the Robert Tucker Hayes Foundation Distinguished Chair in Cardiothoracic Surgery; Dr. Yang Xie, Associate Professor of Clinical Sciences and Bioinformatics; Dr. Hong Zhu, Assistant Professor of Clinical Sciences and with the Simmons Cancer Center; Dr. Farjana Fattah, Assistant Professor with the Simmons Cancer Center and Pathology; Dr. Masaya Takahashi, Associate Professor with the Advanced Imaging Research and Radiology; Dr. Bipasha Mukherjee, Assistant Professor of Radiation Oncology; Dr. Sandeep Burma, Associate Professor of Radiation Oncology; and Dr. Jonathan Dowell, Professor of Internal Mresearch are: Dr. Boning Gao, Assistant Professor with the Hamon Center for Therapeutic Oncology Research and Pharmacology; Dr. Kimmo Hatanpaa, Associate Professor of Pathology; Dr. Kemp Kernstine, Professor of Cardiovascular and Thoracic Surgery and holder of the Robert Tucker Hayes Foundation Distinguished Chair in Cardiothoracic Surgery; Dr. Yang Xie, Associate Professor of Clinical Sciences and Bioinformatics; Dr. Hong Zhu, Assistant Professor of Clinical Sciences and with the Simmons Cancer Center; Dr. Farjana Fattah, Assistant Professor with the Simmons Cancer Center and Pathology; Dr. Masaya Takahashi, Associate Professor with the Advanced Imaging Research and Radiology; Dr. Bipasha Mukherjee, Assistant Professor of Radiation Oncology; Dr. Sandeep Burma, Associate Professor of Radiation Oncology; and Dr. Jonathan Dowell, Professor of Internal MResearch and Pharmacology; Dr. Kimmo Hatanpaa, Associate Professor of Pathology; Dr. Kemp Kernstine, Professor of Cardiovascular and Thoracic Surgery and holder of the Robert Tucker Hayes Foundation Distinguished Chair in Cardiothoracic Surgery; Dr. Yang Xie, Associate Professor of Clinical Sciences and Bioinformatics; Dr. Hong Zhu, Assistant Professor of Clinical Sciences and with the Simmons Cancer Center; Dr. Farjana Fattah, Assistant Professor with the Simmons Cancer Center and Pathology; Dr. Masaya Takahashi, Associate Professor with the Advanced Imaging Research and Radiology; Dr. Bipasha Mukherjee, Assistant Professor of Radiation Oncology; Dr. Sandeep Burma, Associate Professor of Radiation Oncology; and Dr. Jonathan Dowell, Professor of Internal MResearch and Radiology; Dr. Bipasha Mukherjee, Assistant Professor of Radiation Oncology; Dr. Sandeep Burma, Associate Professor of Radiation Oncology; and Dr. Jonathan Dowell, Professor of Internal Medicine;
In 1953, she founded the Cancer Research Institute, which still exists today, to honor her father and advance the field of immunotherapy rResearch Institute, which still exists today, to honor her father and advance the field of immunotherapy researchresearch.
These include the ability to bring new, innovative products to the market; progress in oncology, such as the approval of Genentech's drug Avastin for breast cancer and advances in the use of gene therapy, despite some setbacks; continuing progress in research on stem cells; the emergence of treatments for previously untreated diseases; and solutions for food and fuel shortages, such as biocrops and biofuels.
«Dr. Aplin's major research advance is part of a larger effort by the Sidney Kimmel Cancer Center to develop new strategies for treating melanoma.
«This approach offers a potentially new and safe way of treating liver cancer, and possibly other cancers,» said study senior author Dr. Ian Corbin, Assistant Professor in the Advanced Imaging Research Center (AIRC) and of Internal Medicine at UT Southwestern.
Extending national breast cancer screening programs to women over the age of 70 does not result in a decrease in the numbers of cancers detected at advanced stages, according to new research from The Netherlands.
«We sought to better understand and break down the silos and stovepipes that prevent sharing of information and impede advances in cancer research and treatment, while building a focused and coordinated effort at home and abroad,» they explain.
The initiatives he oversaw at NCI «will greatly accelerate cancer research» and «hold potential and promise for great advances,» von Eschenbach said.
Dr Gerrit - Jan Liefers (MD, PhD), a surgical oncologist and head of the geriatric oncology research group at Leiden University Medical Centre (Leiden, The Netherlands), said: «For a screening program to be effective, one would expect that the incidence of early stage breast cancer would increase while the incidence of advanced stage cancer would decrease because any cancer would have been detected at an earlier stage.
ASCO's hope, she says, is that Biden «will be able to come up with a comprehensive approach to advancing cancer research and care.»
The current standard of care for advanced pancreatic cancer — a combination of nab - paclitaxel and gemcitabine — was developed by TGen and the HonorHealth Research Institute, and approved by the U.S. Food and Drug Administration in 2013.
In the April 25 issue of Cancer Cell, a research team, led by Xin Lu, PhD, Ludwig director and member at the University of Oxford and a team of scientists from both institutions, describes how p53 is silenced in advanced melanomas by a protein named iASPP, and applies that information to restore p53 function in such cells.
The initiative is an extension of Biden's 2016 appointment as head of the Cancer Moonshot Initiative, an assignment President Barack Obama extended, aimed at pulling together federal agencies and private, academic and philanthropic organizations to identify new cancer research topics, break down barriers slowing advances and pinpoint necessary investment areas to advance the fight against cCancer Moonshot Initiative, an assignment President Barack Obama extended, aimed at pulling together federal agencies and private, academic and philanthropic organizations to identify new cancer research topics, break down barriers slowing advances and pinpoint necessary investment areas to advance the fight against ccancer research topics, break down barriers slowing advances and pinpoint necessary investment areas to advance the fight against cancercancer.
Italian researches have demonstrated a better way of determining the aggressiveness of tumors in patients with advanced non-small cell lung cancer (NSCLC).
Last summer, Biden launched the Biden Cancer Initiative along with his wife Dr. Jill Biden to continue, outside the federal government, an effort he has led since 2016 to speed advances in cancer research andCancer Initiative along with his wife Dr. Jill Biden to continue, outside the federal government, an effort he has led since 2016 to speed advances in cancer research andcancer research and care.
The plenary address titled «Punctuated Equilibrium Meets Cancer: Big Promise Requires Big Change» will draw from evolutionary biology's punctuated equilibrium theory to set out why stable systems such as cancer research sometimes require swift and fundamental change to adCancer: Big Promise Requires Big Change» will draw from evolutionary biology's punctuated equilibrium theory to set out why stable systems such as cancer research sometimes require swift and fundamental change to adcancer research sometimes require swift and fundamental change to advance.
After a successful postdoc at the Ontario Cancer Institute, where he developed a proprietary platform for the discovery of novel cancer therapeutic agents, Bray was asked to join the former Amgen Research Institute in Toronto (now called the Advanced Medical Discovery Institute and no longer part of the parent company) as the head of their quantitative biology group and act as liaison to Amgen Inc. in CalifCancer Institute, where he developed a proprietary platform for the discovery of novel cancer therapeutic agents, Bray was asked to join the former Amgen Research Institute in Toronto (now called the Advanced Medical Discovery Institute and no longer part of the parent company) as the head of their quantitative biology group and act as liaison to Amgen Inc. in Califcancer therapeutic agents, Bray was asked to join the former Amgen Research Institute in Toronto (now called the Advanced Medical Discovery Institute and no longer part of the parent company) as the head of their quantitative biology group and act as liaison to Amgen Inc. in California.
«Our findings are encouraging, as they suggest that entolimod can be safely combined with other chemotherapeutic, targeted or immunotherapeutic agents as treatment for advanced and very hard - to - treat cancers,» notes Dr. Adjei, who is Senior Vice President of Clinical Research and the Katherine Anne Gioia Chair in Cancer Medicine at Roswell Park.
«Funding research focused on helping patients survive longer is critical, and studies such as this advance our goal of not only improving treatments for brain cancer, but eventually finding a cure.»
Nevertheless, «from my perspective it's the most transformative advance in cancer research that I know of,» Tuveson says.
It is also important to note that HIV research may lead to advances in the treatment of other viral infections, as well as cancers, metabolic diseases (diabetes, high cholesterol) and other immune system disorders.
Technology developed at Western University and Lawson Health Research Institute can provide a new window into whether or not patients are responding to treatment for advanced ovarian cancer.
In this webinar we will discuss the latest advances in mouse models for cancer research and how they are being applied to help us understand the pathways and mechanisms involved in new immune therapies.
«This research is an important advance in the potential expansion of fertility preservation options for young patients who may not be able to undergo hormone stimulation to induce ovulation before beginning chemotherapy,» says study author Jacqueline S. Jeruss, M.D., Ph.D., associate professor of surgery and director of the Breast Care Center at the University of Michigan Comprehensive Cancer Center.
The application of NGS to breast cancer research has enabled the development of cost - effective, multigene sequencing panels that have advanced our understanding of the disease and may in the future translate into better diagnosis and outcomes for patients.
In a randomized, phase 2 multi-center clinical study, led by Manisha Shah, MD of The Ohio State University Comprehensive Cancer Center — Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC — James), investigators tested the effectiveness of the targeted therapy drug, dabrafenib (pronounced «da bRAF e nib» and marketed as Tafinlar), given alone compared with the same drug given in combination with trametinib (pronounced «tra ME ti nib,» marketed at MeKinist) to treat a subset of advanced papillary thyroid cancer patients with B - raf mutaCancer Center — Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC — James), investigators tested the effectiveness of the targeted therapy drug, dabrafenib (pronounced «da bRAF e nib» and marketed as Tafinlar), given alone compared with the same drug given in combination with trametinib (pronounced «tra ME ti nib,» marketed at MeKinist) to treat a subset of advanced papillary thyroid cancer patients with B - raf mutaCancer Hospital and Richard J. Solove Research Institute (OSUCCC — James), investigators tested the effectiveness of the targeted therapy drug, dabrafenib (pronounced «da bRAF e nib» and marketed as Tafinlar), given alone compared with the same drug given in combination with trametinib (pronounced «tra ME ti nib,» marketed at MeKinist) to treat a subset of advanced papillary thyroid cancer patients with B - raf mutacancer patients with B - raf mutations.
Her research is both translational and clinical in nature and centers on the human genetics of healthy skin aging and diseases related to aging skin, including new treatments for advanced basal cell skin cancers.